Patents by Inventor Kuan-Chun Huang

Kuan-Chun Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 12251386
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: September 29, 2022
    Date of Patent: March 18, 2025
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Methods for the treatment of bladder cancer
    Patent number: 12251394
    Abstract: Provided herein are methods for the treatment of bladder cancer.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 18, 2025
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-Wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20230140327
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: September 29, 2022
    Publication date: May 4, 2023
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 11491163
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: November 8, 2022
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Compounds for the treatment of cancer
    Patent number: 11339188
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: May 24, 2022
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Methods for the Treatment of Bladder Cancer
    Publication number: 20210205348
    Abstract: Provided herein are methods for the treatment of bladder cancer.
    Type: Application
    Filed: May 31, 2019
    Publication date: July 8, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20210137936
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: September 25, 2020
    Publication date: May 13, 2021
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun HUANG, Hyeong Wook CHOI, Kristen SANDERS, Steven MATHIEU, Arani CHANDA, Francis FANG
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 10821113
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: November 3, 2020
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20200299321
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 4, 2020
    Publication date: September 24, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • Compounds for the treatment of cancer
    Patent number: 10618930
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: April 14, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • CYCLIC DI-NUCLEOTIDES DERIVATIVE FOR THE TREATMENT OF CANCER
    Publication number: 20200055883
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 16, 2018
    Publication date: February 20, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20190345192
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 15, 2019
    Publication date: November 14, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20190269692
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: February 8, 2019
    Publication date: September 5, 2019
    Inventors: Kevin Wayne KUNTZ, Kuan-Chun HUANG, Hyeong Wook CHOI, Kristen SANDERS, Steven MATHIEU, Arani CHANDA, Francis FANG
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 10245269
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 2, 2019
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Compounds for the treatment of cancer
    Patent number: 10246480
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: April 2, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik Kim, Frank Fang, Atsushi Endo, Hyeong-Wook Choi, Ming-Hong Hao, Xingfeng Bao, Kuan-Chun Huang
  • Ultraviolet curing module
    Patent number: 10094613
    Abstract: An ultraviolet curing module includes a first light source and a second light source. The first light source is configured to emit ultraviolet with a first spectrum. The first spectrum has a first peak wavelength. The second light source is configured to emit ultraviolet with a second spectrum. The second spectrum has a second peak wavelength. Wherein, a difference between the first peak wavelength and the second peak wavelength is greater than 35 nm, and an irradiation range of ultraviolet of the first light source on an irradiated object at least partially overlaps an irradiation range of ultraviolet of the second light source on the irradiated object.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: October 9, 2018
    Assignee: PlayNitride Inc.
    Inventors: Sheng-Yuan Sun, Robert K. Karlicek, Kuan-Chun Huang
  • SALT FORM OF A HUMAN HISTONE METHYLTRANSFERASE EZH2 INHIBITOR
    Publication number: 20180243316
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Application
    Filed: December 11, 2017
    Publication date: August 30, 2018
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Francis Fang
  • Compounds for the Treatment of Cancer
    Publication number: 20180237468
    Abstract: Provided herein are compounds useful for the treatment of cancer.
    Type: Application
    Filed: February 17, 2018
    Publication date: August 23, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Dae-Shik KIM, Frank FANG, Atsushi ENDO, Hyeong-Wook CHOI, Ming-Hong HAO, Xingfeng BAO, Kuan-Chun HUANG
  • ULTRAVIOLET CURING MODULE
    Publication number: 20180209730
    Abstract: An ultraviolet curing module includes a first light source and a second light source. The first light source is configured to emit ultraviolet with a first spectrum. The first spectrum has a first peak wavelength. The second light source is configured to emit ultraviolet with a second spectrum. The second spectrum has a second peak wavelength. Wherein, a difference between the first peak wavelength and the second peak wavelength is greater than 35 nm, and an irradiation range of ultraviolet of the first light source on an irradiated object at least partially overlaps an irradiation range of ultraviolet of the second light source on the irradiated object.
    Type: Application
    Filed: January 23, 2017
    Publication date: July 26, 2018
    Inventors: Sheng-Yuan Sun, Robert K. Karlicek, Kuan-Chun Huang
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent number: 9872862
    Abstract: Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4?-(morpholinomethyl)-[1,1?-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 23, 2018
    Assignees: Epizyme, Inc., Eisai R&D Management Co., Ltd.
    Inventors: Kevin Wayne Kuntz, Kuan-Chun Huang, Hyeong Wook Choi, Kristen Sanders, Steven Mathieu, Arani Chanda, Frances Fang